313 related articles for article (PubMed ID: 28724377)
1. Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model.
Lai X; Friedman A
BMC Syst Biol; 2017 Jul; 11(1):70. PubMed ID: 28724377
[TBL] [Abstract][Full Text] [Related]
2. Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?
Trojaniello C; Vitale MG; Ascierto PA
Curr Opin Oncol; 2021 Mar; 33(2):133-138. PubMed ID: 33399314
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
4. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
Devji T; Levine O; Neupane B; Beyene J; Xie F
JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543
[TBL] [Abstract][Full Text] [Related]
5. AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.
Caputo E; Miceli R; Motti ML; Taté R; Fratangelo F; Botti G; Mozzillo N; Carriero MV; Cavalcanti E; Palmieri G; Ciliberto G; Pirozzi G; Ascierto PA
J Transl Med; 2014 Jul; 12():216. PubMed ID: 25074438
[TBL] [Abstract][Full Text] [Related]
6. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
[TBL] [Abstract][Full Text] [Related]
7. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
8. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
9. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
Shattuck-Brandt RL; Chen SC; Murray E; Johnson CA; Crandall H; O'Neal JF; Al-Rohil RN; Nebhan CA; Bharti V; Dahlman KB; Ayers GD; Yan C; Kelley MC; Kauffmann RM; Hooks M; Grau A; Johnson DB; Vilgelm AE; Richmond A
Clin Cancer Res; 2020 Jul; 26(14):3803-3818. PubMed ID: 32234759
[TBL] [Abstract][Full Text] [Related]
10. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.
Dulgar O; Kutuk T; Eroglu Z
Am J Clin Dermatol; 2021 Jan; 22(1):1-10. PubMed ID: 33368052
[TBL] [Abstract][Full Text] [Related]
12. BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 Antibody.
Sanlorenzo M; Vujic I; Floris A; Novelli M; Gammaitoni L; Giraudo L; Macagno M; Leuci V; Rotolo R; Donini C; Basiricò M; Quaglino P; Fierro MT; Giordano S; Sibilia M; Carnevale-Schianca F; Aglietta M; Sangiolo D
Clin Cancer Res; 2018 Jul; 24(14):3377-3385. PubMed ID: 29650750
[No Abstract] [Full Text] [Related]
13. Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.
Saab KR; Mooradian MJ; Wang DY; Chon J; Xia CY; Bialczak A; Abbate KT; Menzies AM; Johnson DB; Sullivan RJ; Shoushtari AN
Cancer; 2019 Mar; 125(6):884-891. PubMed ID: 30521084
[TBL] [Abstract][Full Text] [Related]
14. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma.
Richman J; Martin-Liberal J; Diem S; Larkin J
Expert Opin Pharmacother; 2015 Jun; 16(9):1285-97. PubMed ID: 26001180
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.
Menzies AM; Long GV
Eur J Cancer; 2013 Oct; 49(15):3229-41. PubMed ID: 23870385
[TBL] [Abstract][Full Text] [Related]
16. Overcoming Drug Resistance to BRAF Inhibitor.
Friedman A; Siewe N
Bull Math Biol; 2020 Jan; 82(1):8. PubMed ID: 31933021
[TBL] [Abstract][Full Text] [Related]
17. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.
Simeone E; Grimaldi AM; Festino L; Vanella V; Palla M; Ascierto PA
BioDrugs; 2017 Feb; 31(1):51-61. PubMed ID: 28058658
[TBL] [Abstract][Full Text] [Related]
18. Clinical Development of BRAF plus MEK Inhibitor Combinations.
Subbiah V; Baik C; Kirkwood JM
Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
[TBL] [Abstract][Full Text] [Related]
19. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF
van Breeschoten J; Wouters MWJM; Hilarius DL; Haanen JB; Blank CU; Aarts MJB; van den Berkmortel FWPJ; de Groot JB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Blokx WAM; Tije BJT; Veldt AAMV; Vreugdenhil A; Boers-Sonderen MJ; van den Eertwegh AJM
Br J Cancer; 2021 Mar; 124(7):1222-1230. PubMed ID: 33495600
[TBL] [Abstract][Full Text] [Related]
20. First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.
Schilling B; Martens A; Geukes Foppen MH; Gebhardt C; Hassel JC; Rozeman EA; Gesierich A; Gutzmer R; Kähler KC; Livingstone E; Diamantopoulos PT; Gogas H; Madonna G; Ascierto PA; Goldinger SM; Mangana J; Garbe C; Schadendorf D; Blank C; Weide B
Cancer Immunol Immunother; 2019 May; 68(5):765-772. PubMed ID: 30806748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
